MannKind | MNKD - Debt


MannKind reported $119.91M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Adma Biologics USD 83.12M 702K Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Eli Lilly USD 42.51B 2.6B Sep/2025
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Insmed USD 727.89M 163.33M Dec/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
MannKind USD 119.91M 73.09M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 233.31M 4.23M Sep/2024
Novo Nordisk DKK 118.72B 15.94B Mar/2025
Pfizer USD 60.85B 78M Sep/2025
Sanofi EUR 20.33B 1.43B Dec/2025
Xencor USD 69.27M 1.34M Sep/2025